TTRX
NASDAQ · Pharmaceuticals
Turn Therapeutics Inc
$3.80
+0.11 (+2.97%)
Financial Highlights (FY 2025)
Revenue
28.41M
Net Income
5.07M
Gross Margin
60.5%
Profit Margin
17.8%
Rev Growth
+18.7%
D/E Ratio
0.72
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 60.5% | 60.5% | 60.5% |
| Operating Margin | 23.8% | 22.7% | 22.9% |
| Profit Margin | 17.8% | 15.3% | 16.6% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.41M | 28.26M | 24.54M |
| Gross Profit | 17.18M | 17.09M | 14.84M |
| Operating Income | 6.77M | 6.40M | 5.61M |
| Net Income | 5.07M | 4.33M | 4.07M |
| Gross Margin | 60.5% | 60.5% | 60.5% |
| Operating Margin | 23.8% | 22.7% | 22.9% |
| Profit Margin | 17.8% | 15.3% | 16.6% |
| Rev Growth | +18.7% | -2.9% | -7.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 52.60M | 49.37M | 49.93M |
| Total Equity | 73.19M | 64.37M | 61.81M |
| D/E Ratio | 0.72 | 0.77 | 0.81 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.12M | 6.76M | 5.89M |
| Free Cash Flow | 5.68M | 5.26M | 4.99M |